Alexander's, Inc. (ALX)

PARAMUS, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it has completed a $175 million refinancing of its 615,000 square foot Rego Park II shopping center located in Queens, New York. The interest-only loan is at SOFR plus 2.00%, currently 5.82%, and matures in December 2030.

We contrarians follow Wall Street analysts because we like to fade their opinions!

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in both the Jefferies Global Healthcare Conference in London and Piper Sandler 37th Annual Global Healthcare Conference in New York.

ALX, PFBC and WFRD made it to the Zacks Rank #1 (Strong Buy) income stocks list on Nov. 13, 2025.

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update.

Here is how Alexander's (ALX) and Affiliated Managers Group (AMG) have performed compared to their sector so far this year.

ALX Oncology (NASDAQ: ALXO - Get Free Report) is expected to be posting its Q3 2025 results before the market opens on Friday, November 7th. Analysts expect ALX Oncology to post earnings of ($0.37) per share for the quarter. Interested persons may review the information on the company's upcoming Q3 2025 earningreport for the latest details

PARAMUS, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended September 30, 2025 today and reported:

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its third quarter 2025 financial results and provide a business update on Friday, November 7th, 2025, before market open.

In trading on Wednesday, shares of Alexander's were yielding above the 8% mark based on its quarterly dividend (annualized to $18), with the stock changing hands as low as $224.25 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return.

PARAMUS, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on November 28, 2025 to stockholders of record on November 10, 2025.

-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors

PARAMUS, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended September 30, 2025 with the U.S. Securities and Exchange Commission and issue its third quarter earnings release on Monday, November 3, 2025, before the New York Stock Exchange opens.

High-yield REITs with low Dividend Safety grades often signal an elevated risk of dividend cuts and rapid share price declines, making them potential "mousetraps" for income investors. This article highlights 23 equity REITs with yields above 5.25% and Dividend Safety ratings in the Danger Zone (D or F), focusing on six with an F grade. Key risk factors include unsustainable payout ratios, declining FFO, and high debt metrics, increasing the likelihood of dividend cuts within the next 12 months.

AHCO, ALX and CAG have been added to the Zacks Rank #5 (Strong Sell) List on September 22, 2025.

SOUTH SAN FRANCISCO, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced the appointment of Dr. Klencke to the role of Interim Chief Medical Officer (CMO) on a full-time basis. Dr. Alan Sandler is departing from the role of CMO and will return to his former position on the ALX Oncology Board of Directors (BOD), where he previously served.